Latest Articles and Analysis

Health misinformation undermines vaccine confidence, perpetuates stigma, and drives poor policy decisions.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

Pediatric hepatitis investigations lack typical viruses but show adenovirus and potential COVID-19 involvement.

PrEP access remains limited by payer practices like prior authorizations despite ACA coverage requirements.

Restrictions on abortion and transgender care represent broader attacks on medication access as human right.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.

CANN campaign promotes transgender leadership in HIV advocacy, affirming gender-affirming care as lifesaving.

Biden's SOTU addresses harm reduction, endorses MAT Act; limited HIV-specific programming focus.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

Family support predicts treatment success; policy must address intimate partner violence and health outcomes.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

MAT Act removes X-waiver requirements, expanding buprenorphine access especially in rural communities.

Access Health Louisiana uses animated series and radio to educate communities on HIV, HCV, and public health.

NIH issues RFAs for Harm Reduction Network; Biden agenda targets decriminalization and safe consumption.